Similar companies
Income Statement (CAD)
| Q3 '25 | QoQ | |
|---|---|---|
| Operating expense | 10M | 32.6% |
| Net Income | -10M | 19.3% |
| EBITDA | -9.9M | 29.9% |
Balance Sheet (CAD)
| Q3 '25 | QoQ | |
|---|---|---|
| Total Assets | 13M | 35.1% |
| Total Liabilities | 3.4M | 58.3% |
| Total Equity | 9.6M | 19% |
| Shares Outstanding | 85M | 2.5% |
Cash Flow (CAD)
| Q3 '25 | QoQ | |
|---|---|---|
| Cash from operations | -6.9M | 52.2% |
| Cash from investing | -3,000 | 53.1% |
| Cash from financing | -14,000 | 167.8% |
Financial Highlights for Cardiol Therapeutics in Q3 '25
Operating Expenses for this period were 10M, showing a 32.6% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -10M, showing a -19.3% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -9.9M, showing a -29.9% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
Cardiol Therapeutics faced some challenges this quarter with a decline in one or more of the key metrics: revenue, gross profit, or net income. Higher operating expenses might indicate increased investments or potential inefficiencies. A decline in EBITDA signals potential operational challenges or increased costs.
